HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.049932v1 49/8/1262    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mikhno, A. Articles by Parsey, R. V. Search for Related Content PubMed PubMed Citation Articles by Mikhno, A. Articles by Parsey, R. V.

Voxel-Based Analysis of ¹¹C-PIB Scans for Diagnosing Alzheimer's Disease

¹ Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York; ² Columbia University, New York, New York; ³ Department of Geriatric Depression, New York State Psychiatric Institute, New York, New York; and ⁴ GlaxoSmithKline CPDM and Neurology-CEDD, Essex, United Kingdom

Correspondence: For correspondence or reprints contact: Arthur Mikhno, 1051 Riverside Dr., Manhattan, NY 10032. E-mail: am2679{at}columbia.edu

The positron emission tomography (PET) radioligand N-methyl-¹¹C-2-(4-methylaminophenyl)-6-hydroxybenzothiazole (also known as ¹¹C-6-OH-BTA-1 or ¹¹C-PIB) binds to amyloid-β (Aβ), which accumulates pathologically in Alzheimer's disease (AD). Although ¹¹C-PIB accumulation is greater in patients with AD than in healthy controls at a group level, the optimal method for discriminating between these 2 groups has, to our knowledge, not been established. We assessed the use of data-determined standardized voxels of interest (VOIs) to improve the classification capability of ¹¹C-PIB scans on patients with AD. Methods: A total of 16 controls and 14 AD age-matched patients were recruited. All subjects underwent a ¹¹C-PIB scan and structural MRI. Binding potential (a measure of amyloid burden) was calculated for each voxel using the Logan graphical method with cerebellar gray matter as the reference region. Voxel maps were then partial-volume corrected and spatially normalized by MRI onto a standardized template. The subjects were divided into 2 cohorts. The first cohort (control, 12; AD, 9) was used for statistical parametric mapping analysis and delineation of data-based VOIs. These VOIs were tested in the second cohort (control, 4; AD, 5) of subjects. Results: Statistical parametric mapping analysis revealed significant differences between control and AD groups. The VOI map determined from the first cohort resulted in complete separation between the control and the AD subjects in the second cohort (P < 0.02). Binding potential values based on this VOI were in the same range as other reported individual and mean cortical VOI results. Conclusion: A standardized VOI template that is optimized for control or AD group discrimination provides excellent separation of control and AD subjects on the basis of ¹¹C-PIB uptake. This VOI template can serve as a potential replacement for manual VOI delineation and can eventually be fully automated, facilitating potential use in a clinical setting. To facilitate independent analysis and validation with more and a broader variety of subjects, this VOI template and the software for processing will be made available through the Internet.

Key Words: PET • PIB • Alzheimer's • diagnosis • voxel

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]